ADELAIDE, Australia—Nova Eye Medical Limited (ASX: EYE), an ophthalmic technology company based here, is launching the iTrack Global Data Registry to collect prospective, multicenter, longitudinal data for canaloplasty in the treatment of glaucoma. A collaboration with the International Glaucoma Surgery Registry (IGSR), the iTrack Global Data Registry will be led by world-renowned surgeons Iqbal Ike K. Ahmed, MD FRCSC (John A. Moran Eye Center, Utah, USA and Prism Eye Institute, Toronto, Canada), David Lubeck, MD (Arbor Centers for EyeCare, Chicago, USA) and Nathan Kerr, BHB, MBChB, MD, FRANZCO (Eye Surgery Associates, Melbourne, Australia), with the support of an educational grant from Nova Eye Medical.

The iTrack Global Data Registry will capture real-world clinical evidence for canaloplasty across Europe, the Asia Pacific region and North America, Nova Eye Medical said in an announcement. The company’s portfolio of proprietary canaloplasty devices—the iTrack and iTrack Advance—will be featured in the Registry.
Dr. Kerr is a founder of the IGSR and has spearheaded the development of the iTrack Global Data Registry. He presented an interim data analysis for the iTrack Global Data Registry during the Asia Pacific Glaucoma Congress (APGC), August 4-7, 2022, in Malaysia.
“The iTrack Global Data Registry is providing high-quality, real-world evidence of the effectiveness and safety of canaloplasty to treat glaucoma and ocular hypertension. Importantly, it provides a robust means by which to collect uniform data to evaluate specified outcomes across the spectrum of glaucoma. It will make a major contribution to our understanding of the clinical effectiveness of canaloplasty and will enable evidence-based decision making,” commented Dr. Kerr.
The iTrack Global Data Registry will follow canaloplasty outcomes for a minimum of 24 months and will enroll more than 300 patients.